Rx Industry CEOs Are Taking “Positive” Steps On GMPs, FDA’s Galson Says
Executive Summary
FDA's discussions with pharmaceutical industry CEOs over the past year give the agency confidence that manufacturing quality is improving, Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, told the Schwab Washington Research Group conference May 2
You may also be interested in...
Schering NDAs Are Clear For Review Under FDA Consent Decree
Schering-Plough NDAs will not be subject to extra scrutiny under the GMP consent decree with FDA
Schering NDAs Are Clear For Review Under FDA Consent Decree
Schering-Plough NDAs will not be subject to extra scrutiny under the GMP consent decree with FDA
FDA PAT Inspection Teams Being Formed: Further Training Set For Fall
FDA is assembling review/inspection teams to help evaluate upcoming industry submissions involving implementation of process analytical technologies in manufacturing